Johnson & Johnson Stock Trending Among Wall Street Analysts

Johnson & Johnson (JNJ) stock has fallen 0.71% over the past week but gained 5.94% in the last month and an impressive 54.66% over the past year. Wall Street’s analysts are moderately bullish, with a consensus “Moderate Buy” rating and an average 12‑month price target of $224.91 versus the last closing price of $218.01. That implies modest upside from here, suggesting that while the big re-rating may be behind the stock, analysts still see room for further gains.

A key bull voice is Josh Jennings, who reiterated his Buy rating on Johnson & Johnson and raised his price target to $250.00. His new target is based on 20x projected 2027 earnings per share, signaling confidence in the company’s long-term profit growth. Jennings argues that Johnson & Johnson is well positioned to generate sustained momentum after delivering solid fourth-quarter results that beat consensus, with $24.6 billion in revenue coming in ahead of Street expectations.

Jennings highlights that initial 2026 guidance should push revenue and EPS estimates higher, supported by strength across both the Pharma and Devices businesses. The company expects adjusted operational revenue growth of 5.7%–6.7% in 2026, translating to $99.5–$100.5 billion in sales. With FX tailwinds, reported revenue could reach $100.0–$101.0 billion, implying about 6.7% growth at the midpoint. Johnson & Johnson also projects at least a 50-basis-point improvement in adjusted operating margin, even as it steps up investment in new product launches and its pipeline, while navigating roughly $500 million in MedTech tariffs.

On the product side, Jennings points to growth drivers in the Innovative Medicine segment, led by Tremfya in Immunology; Darzalex, Carvykti, and Erleada in Oncology; and Spravato in Neuroscience. Newer launches such as Rybrevant/Lazcluze in lung cancer and Caplyta for major depressive disorder are expected to contribute more as 2026 progresses. At the same time, he notes ongoing headwinds from Stelara’s erosion, rising generic competition for Simponi and Opsumit, and the impact of Johnson & Johnson’s voluntary agreement with the U.S. government, which is expected to be spread evenly through the year. Jennings ranks 2,296 out of 11,984 analysts on TipRanks, with a 49.30% success rate and an average return of 4.90% per rating.

Balancing that bullish stance, analyst Jason Gerberry reiterated a Hold (Neutral) rating on Johnson & Johnson with a slightly increased price objective of $221.00, just above the current share price. Gerberry modestly raised his 2026 sales and EPS estimates after a solid fourth quarter driven by core growth drivers such as Tremfya, Darzalex, Erleada, and slightly stronger Orthopedics and Vision, partly offset by weaker Stelara. However, he flagged that recent talc litigation headlines have weighed on the shares and introduced some uncertainty about potential costs, even if it is not yet clear whether those costs could be material for a company of Johnson & Johnson’s size. Gerberry values the stock at a blended 17.5x 2027 EPS, arguing that its premium multiple already reflects a de‑risked long-term growth outlook and that he remains cautious on the new product cycle. This 4‑star analyst ranks 324 out of 11,984 on TipRanks, with a 61.73% success rate and a strong 15.50% average return per rating. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.